NVS Jan 2025 92.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:26AM EDT
Loading interactive chart…
- Zacks
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
- Investor's Business Daily
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?
- Zacks
Here's Why Novartis (NVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
© 2024 Yahoo. All rights reserved.